Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infection

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516266-11-00

Acronym

PI2018_843_0007

Enrollment

448

Registered

2024-08-13

Start date

2020-01-06

Completion date

Unknown

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritonitis, yeast intra-abdominal infection

Brief summary

28-day failure rate after the beginning of treatment

Detailed description

28 and 90-day mortality, Success rate at the end of treatment, Slope of ß-D-glucan concentrations, 28-day mortality for subgroup analysis

Interventions

DRUGSodium Chloride B Braun 0

DRUG9% süstelahus

DRUGCANCIDAS 50 mg powder for concentrate for solution for infusion

DRUGCANCIDAS 70 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
28-day failure rate after the beginning of treatment	—

Secondary

Measure	Time frame
28 and 90-day mortality, Success rate at the end of treatment, Slope of ß-D-glucan concentrations, 28-day mortality for subgroup analysis	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026